164 related articles for article (PubMed ID: 3815352)
21. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
Voelcker G; Haeglsperger R
Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats.
Powers JF; Sladek NE
Cancer Res; 1983 Mar; 43(3):1101-6. PubMed ID: 6825082
[No Abstract] [Full Text] [Related]
24. Causes and possibilities to circumvent cyclophosphamide toxicity.
Voelcker G
Anticancer Drugs; 2020 Jul; 31(6):617-622. PubMed ID: 32044797
[TBL] [Abstract][Full Text] [Related]
25. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.
Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR
J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655
[TBL] [Abstract][Full Text] [Related]
26. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Voelcker G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
[TBL] [Abstract][Full Text] [Related]
27. Cross-linking of DNA in L1210 cells and nuclei treated with cyclophosphamide and phosphoramide mustard.
Surya YA; Rosenfeld JM; Hillcoat BL
Cancer Treat Rep; 1978 Jan; 62(1):23-9. PubMed ID: 564237
[TBL] [Abstract][Full Text] [Related]
28. A comparison of sister-chromatid exchange in mouse peripheral blood lymphocytes exposed in vitro and in vivo to phosphoramide mustard and 4-hydroxycyclophosphamide.
Bryant MF; Erexson GL; Kligerman AD
Mutat Res; 1989 Mar; 222(3):271-7. PubMed ID: 2922010
[TBL] [Abstract][Full Text] [Related]
29. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro.
Hales BF
Teratology; 1989 Jul; 40(1):11-20. PubMed ID: 2763206
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis.
Belfayol-Pisanté L; Guillevin L; Tod M; Fauvelle F
Fundam Clin Pharmacol; 2000; 14(4):415-21. PubMed ID: 11030450
[TBL] [Abstract][Full Text] [Related]
31. Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs.
Tietze LF; Neumann M; Möllers T; Fischer R; Glüsenkamp KH; Rajewsky MF; Jähde E
Cancer Res; 1989 Aug; 49(15):4179-84. PubMed ID: 2743306
[TBL] [Abstract][Full Text] [Related]
32. In vitro alteration of canine renal allografts with cyclophosphamide metabolites.
Zincke H; Jardine I; Colvin M; Aydin G; Okiye SE
Transplant Proc; 1983 Jun; 15(2):1698-701. PubMed ID: 6349051
[TBL] [Abstract][Full Text] [Related]
33. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.
Fetting JH; McCarthy LE; Borison HL; Colvin M
Cancer Treat Rep; 1982 Aug; 66(8):1625-9. PubMed ID: 7105052
[TBL] [Abstract][Full Text] [Related]
34. N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard.
Jiang Y; Hu L
Bioorg Med Chem Lett; 2008 Jul; 18(14):4059-63. PubMed ID: 18556201
[TBL] [Abstract][Full Text] [Related]
35. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues.
Kwon CH; Borch RF
J Med Chem; 1989 Jul; 32(7):1491-6. PubMed ID: 2738883
[TBL] [Abstract][Full Text] [Related]
36. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.
Struck RF; Alberts DS; Horne K; Phillips JG; Peng YM; Roe DJ
Cancer Res; 1987 May; 47(10):2723-6. PubMed ID: 3552204
[TBL] [Abstract][Full Text] [Related]
37. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide.
Parekh HK; Sladek NE
Biochem Pharmacol; 1993 Sep; 46(6):1043-52. PubMed ID: 8216347
[TBL] [Abstract][Full Text] [Related]
38. Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.
Zaharko DS; Covey JM; Hörpel G
Invest New Drugs; 1984; 2(2):149-54. PubMed ID: 6469508
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein.
Hales BF
Cancer Res; 1982 Aug; 42(8):3016-21. PubMed ID: 7046914
[No Abstract] [Full Text] [Related]
40. Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.
Manthey CL; Sladek NE
Biochem Pharmacol; 1988 Jul; 37(14):2781-90. PubMed ID: 3395357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]